Italia markets close in 3 hours 10 minutes

Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,0800-0,0200 (-1,82%)
Alla chiusura: 04:00PM EDT
1,1300 +0,05 (+4,63%)
Preborsa: 08:00AM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,1000
Aperto1,1000
Denaro1,0600 x 100
Lettera1,1300 x 100
Min-Max giorno1,0800 - 1,1100
Intervallo di 52 settimane0,8400 - 2,0300
Volume22.264
Media Volume129.022
Capitalizzazione41,178M
Beta (5 anni mensile)0,99
Rapporto PE (ttm)N/D
EPS (ttm)-1,8300
Prossima data utili09 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A4,54
  • GlobeNewswire

    Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

    REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that updated clinical data from its Phase 1/2 dose-escalation study of BDC-1001 will be presented in a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain and virtually from October 20-24, 2023. BDC-10

  • GlobeNewswire

    Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

    BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001 Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal junction cancer REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t

  • GlobeNewswire

    Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

    REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023. “The issuance of this patent is an important milestone in protecting the comp